Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Safety of HBI0101 (NXC-201), a novel academic anti-BCMA CAR-T, in R/R AL amyloidosis

Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, shares the results of a Phase I/II study evaluating HBI0101 (NXC-201), a novel academic anti-BCMA CAR-T cell, in patients with relapsed/refractory (R/R) light chain (AL) amyloidosis (NCT04720313). Dr Lebel summarizes the safety profile of this agent, including the rates of cytokine release syndrome (CRS) and hematological toxicity observed, and concludes by commenting on the response rates demonstrated in this study. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.